427 related articles for article (PubMed ID: 23986593)
1. Assessing activity and inhibition of Middle East respiratory syndrome coronavirus papain-like and 3C-like proteases using luciferase-based biosensors.
Kilianski A; Mielech AM; Deng X; Baker SC
J Virol; 2013 Nov; 87(21):11955-62. PubMed ID: 23986593
[TBL] [Abstract][Full Text] [Related]
2. The SARS-coronavirus papain-like protease: structure, function and inhibition by designed antiviral compounds.
Báez-Santos YM; St John SE; Mesecar AD
Antiviral Res; 2015 Mar; 115():21-38. PubMed ID: 25554382
[TBL] [Abstract][Full Text] [Related]
3. Inhibitor recognition specificity of MERS-CoV papain-like protease may differ from that of SARS-CoV.
Lee H; Lei H; Santarsiero BD; Gatuz JL; Cao S; Rice AJ; Patel K; Szypulinski MZ; Ojeda I; Ghosh AK; Johnson ME
ACS Chem Biol; 2015 Jun; 10(6):1456-65. PubMed ID: 25746232
[TBL] [Abstract][Full Text] [Related]
4. Synonymous and Biased Codon Usage by MERS CoV Papain-Like and 3CL-Proteases.
Kandeel M; Altaher A
Biol Pharm Bull; 2017 Jul; 40(7):1086-1091. PubMed ID: 28420819
[TBL] [Abstract][Full Text] [Related]
5. Proteolytic processing, deubiquitinase and interferon antagonist activities of Middle East respiratory syndrome coronavirus papain-like protease.
Yang X; Chen X; Bian G; Tu J; Xing Y; Wang Y; Chen Z
J Gen Virol; 2014 Mar; 95(Pt 3):614-626. PubMed ID: 24362959
[TBL] [Abstract][Full Text] [Related]
6. Structurally Guided Removal of DeISGylase Biochemical Activity from Papain-Like Protease Originating from Middle East Respiratory Syndrome Coronavirus.
Daczkowski CM; Goodwin OY; Dzimianski JV; Farhat JJ; Pegan SD
J Virol; 2017 Dec; 91(23):. PubMed ID: 28931677
[TBL] [Abstract][Full Text] [Related]
7. Effective inhibition of coronavirus replication by
Xu H; Li J; Song S; Xiao Z; Chen X; Huang B; Sun M; Su G; Zhou D; Wang G; Hao R; Wang N
Front Biosci (Landmark Ed); 2021 Oct; 26(10):789-798. PubMed ID: 34719206
[No Abstract] [Full Text] [Related]
8. Ligand-induced Dimerization of Middle East Respiratory Syndrome (MERS) Coronavirus nsp5 Protease (3CLpro): IMPLICATIONS FOR nsp5 REGULATION AND THE DEVELOPMENT OF ANTIVIRALS.
Tomar S; Johnston ML; St John SE; Osswald HL; Nyalapatla PR; Paul LN; Ghosh AK; Denison MR; Mesecar AD
J Biol Chem; 2015 Aug; 290(32):19403-22. PubMed ID: 26055715
[TBL] [Abstract][Full Text] [Related]
9. Catalytic function and substrate specificity of the papain-like protease domain of nsp3 from the Middle East respiratory syndrome coronavirus.
Báez-Santos YM; Mielech AM; Deng X; Baker S; Mesecar AD
J Virol; 2014 Nov; 88(21):12511-27. PubMed ID: 25142582
[TBL] [Abstract][Full Text] [Related]
10. A chimeric virus-mouse model system for evaluating the function and inhibition of papain-like proteases of emerging coronaviruses.
Deng X; Agnihothram S; Mielech AM; Nichols DB; Wilson MW; StJohn SE; Larsen SD; Mesecar AD; Lenschow DJ; Baric RS; Baker SC
J Virol; 2014 Oct; 88(20):11825-33. PubMed ID: 25100850
[TBL] [Abstract][Full Text] [Related]
11. BRET-Based Self-Cleaving Biosensors for SARS-CoV-2 3CLpro Inhibitor Discovery.
Hou N; Peng C; Zhang L; Zhu Y; Hu Q
Microbiol Spectr; 2022 Aug; 10(4):e0255921. PubMed ID: 35758897
[TBL] [Abstract][Full Text] [Related]
12. Detecting SARS-CoV-2 3CLpro expression and activity using a polyclonal antiserum and a luciferase-based biosensor.
O'Brien A; Chen DY; Hackbart M; Close BJ; O'Brien TE; Saeed M; Baker SC
Virology; 2021 Apr; 556():73-78. PubMed ID: 33548599
[TBL] [Abstract][Full Text] [Related]
13. A safe and convenient pseudovirus-based inhibition assay to detect neutralizing antibodies and screen for viral entry inhibitors against the novel human coronavirus MERS-CoV.
Zhao G; Du L; Ma C; Li Y; Li L; Poon VK; Wang L; Yu F; Zheng BJ; Jiang S; Zhou Y
Virol J; 2013 Aug; 10():266. PubMed ID: 23978242
[TBL] [Abstract][Full Text] [Related]
14. Structural and functional characterization of MERS coronavirus papain-like protease.
Lin MH; Chuang SJ; Chen CC; Cheng SC; Cheng KW; Lin CH; Sun CY; Chou CY
J Biomed Sci; 2014 Jun; 21(1):54. PubMed ID: 24898546
[TBL] [Abstract][Full Text] [Related]
15. Characteristics of flavonoids as potent MERS-CoV 3C-like protease inhibitors.
Jo S; Kim H; Kim S; Shin DH; Kim MS
Chem Biol Drug Des; 2019 Dec; 94(6):2023-2030. PubMed ID: 31436895
[TBL] [Abstract][Full Text] [Related]
16. Prediction and biochemical analysis of putative cleavage sites of the 3C-like protease of Middle East respiratory syndrome coronavirus.
Wu A; Wang Y; Zeng C; Huang X; Xu S; Su C; Wang M; Chen Y; Guo D
Virus Res; 2015 Oct; 208():56-65. PubMed ID: 26036787
[TBL] [Abstract][Full Text] [Related]
17. Characterization and Noncovalent Inhibition of the Deubiquitinase and deISGylase Activity of SARS-CoV-2 Papain-Like Protease.
Freitas BT; Durie IA; Murray J; Longo JE; Miller HC; Crich D; Hogan RJ; Tripp RA; Pegan SD
ACS Infect Dis; 2020 Aug; 6(8):2099-2109. PubMed ID: 32428392
[TBL] [Abstract][Full Text] [Related]
18. MERS-CoV papain-like protease has deISGylating and deubiquitinating activities.
Mielech AM; Kilianski A; Baez-Santos YM; Mesecar AD; Baker SC
Virology; 2014 Feb; 450-451():64-70. PubMed ID: 24503068
[TBL] [Abstract][Full Text] [Related]
19. Identification and evaluation of potent Middle East respiratory syndrome coronavirus (MERS-CoV) 3CL
Kumar V; Shin JS; Shie JJ; Ku KB; Kim C; Go YY; Huang KF; Kim M; Liang PH
Antiviral Res; 2017 May; 141():101-106. PubMed ID: 28216367
[TBL] [Abstract][Full Text] [Related]
20. Coronaviruses resistant to a 3C-like protease inhibitor are attenuated for replication and pathogenesis, revealing a low genetic barrier but high fitness cost of resistance.
Deng X; StJohn SE; Osswald HL; O'Brien A; Banach BS; Sleeman K; Ghosh AK; Mesecar AD; Baker SC
J Virol; 2014 Oct; 88(20):11886-98. PubMed ID: 25100843
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
